Maze Therapeutics CEO sells 22,638 shares

Maze Therapeutics’ CEO sold shares to cover RSU-related tax withholding while maintaining substantial indirect holdings through family trusts.

Rhea-AI Filing Summary

Maze Therapeutics, Inc. (MAZE) reported that Chief Executive Officer and director Jason V. Coloma sold an aggregate of 22,638 shares of Common Stock on September 2–3, 2026, in open-market or private transactions to satisfy tax withholding obligations incurred upon the vesting of restricted stock units.

The reported weighted average prices were $26.3760 and $27.1211 per share on September 2, 2026, and $26.0133 and $25.7749 per share on September 3, 2026, with individual trades executed within the price ranges described in the footnotes. Coloma is also reported as having indirect ownership of 18,151 shares held by The Coloma 2021 Irrevocable Trust and 223,355 shares held by the Coloma Family Trust, for which he and his spouse serve as co‑trustees.

Insider Trade Summary

Net Seller: 22,638 shares

Net Sell 6 txns

Insider Coloma Jason V

Role Chief Executive Officer

Sold 22,638 shs ($594K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F4	11,282	$26.0133	$293K
Sale	Common Stock F1	129	$25.7749	$3K
Sale	Common Stock F1, F2	9,852	$26.376	$260K
Sale	Common Stock F1, F3	1,375	$27.1211	$37K
holding	Common Stock F5	--	--	--
holding	Common Stock F6	--	--	--

Holdings After Transaction: Common Stock — 27,362 shares (Direct); Common Stock — 18,151 shares (Indirect, The Coloma 2021 Irrevocable Trust); Common Stock — 223,355 shares (Indirect, Coloma Family Trust)

Footnotes (6)

1. F1. The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $27.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.055 to $27.40 per share, inclusive.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.743 to $26.65 per share, inclusive.
5. F5. These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees.
6. F6. These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees.

Key Figures

Total shares sold: 22,638 shares Sale price (weighted average) 1: $26.3760 per share Sale price (weighted average) 2: $27.1211 per share +5 more

8 metrics

Total shares sold 22,638 shares Common Stock sales by CEO Jason V. Coloma on September 2–3, 2026

Sale price (weighted average) 1 $26.3760 per share Sale of 9,852 shares of Common Stock on September 2, 2026

Sale price (weighted average) 2 $27.1211 per share Sale of 1,375 shares of Common Stock on September 2, 2026

Sale price (weighted average) 3 $26.0133 per share Sale of 11,282 shares of Common Stock on September 3, 2026

Sale price (weighted average) 4 $25.7749 per share Sale of 129 shares of Common Stock on September 3, 2026

Indirect trust holdings (Coloma 2021 Irrevocable Trust) 18,151 shares Common Stock indirectly held with Jason V. Coloma and spouse as co‑trustees

Indirect trust holdings (Coloma Family Trust) 223,355 shares Common Stock indirectly held with Jason V. Coloma and spouse as co‑trustees

Net buy/sell direction Net sale of 22,638 shares Across all reported non-derivative transactions in this Form 4

Key Terms

restricted stock units, tax withholding obligations, weighted average price, Irrevocable Trust, +1 more

5 terms

restricted stock units financial

"incurred in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold to satisfy tax withholding obligations incurred in connection"

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Irrevocable Trust financial

"directly held by The Coloma 2021 Irrevocable Trust, for which"

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

co-trustees financial

"for which the reporting person and his spouse serve as co-trustees"

FAQ

How many MAZE shares did CEO Jason V. Coloma sell in this Form 4?

Jason V. Coloma reported selling a total of 22,638 shares of Maze Therapeutics Common Stock on September 2 and 3, 2026, across four open‑market or private sale transactions.

Why were the MAZE shares sold by the CEO in this Form 4?

The filing states the reported transactions represent shares of Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units.

At what prices were MAZE shares sold in the CEO’s September 2026 transactions?

Reported weighted average sale prices were $26.3760 and $27.1211 per share on September 2, 2026, and $26.0133 and $25.7749 per share on September 3, 2026, with actual trade prices within specified ranges.

Does the MAZE Form 4 indicate sales under a Rule 10b5-1 trading plan?

No. The document-level checkbox for Rule 10b5-1 is unchecked, and the footnotes do not state that the transactions were made pursuant to a Rule 10b5-1 trading plan.

What indirect MAZE shareholdings are reported for the CEO?

Indirect holdings reported include 18,151 shares held by The Coloma 2021 Irrevocable Trust and 223,355 shares held by the Coloma Family Trust, with Jason V. Coloma and his spouse serving as co‑trustees for each trust.

How are the MAZE sale prices described in the Form 4 footnotes?

For three of the sale entries, the filing explains that the reported prices are weighted average prices for multiple transactions executed within specified price ranges, and detailed breakdowns are available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:25 PM Accepted by SEC EDGAR 09/04/2026 - 04:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coloma Jason V

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		S(1)		9,852	D	$26.376(2)	40,148	D
Common Stock	09/02/2026		S(1)		1,375	D	$27.1211(3)	38,773	D
Common Stock	09/03/2026		S(1)		11,282	D	$26.0133(4)	27,491	D
Common Stock	09/03/2026		S(1)		129	D	$25.7749	27,362	D
Common Stock								18,151	I	The Coloma 2021 Irrevocable Trust(5)
Common Stock								223,355	I	Coloma Family Trust(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $27.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.055 to $27.40 per share, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.743 to $26.65 per share, inclusive.

5. These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees.

6. These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees.

	/s/ Courtney Phillips, as attorney-in-fact	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)